Telemetry Leads Lead Optimization
Eeny Meeny Miney Mo…Where Should My R&D Dollars Go?
Do you have compounds with promise, but not enough resources to investigate all of them? I know I did when I managed projects teams and it’s a daily concern for our current clients.
This is why lead optimization screening in drug discovery and safety assessment became a cornerstone of the CorDynamics services and capabilities offerings when we started the company 10 years ago.
GLP Telemetry Vs. Lead Optimization Telemetry
Determining which lead compounds to put your R&D dollars behind is even more imperative in today’s environment. Based on this premise, our team has taken the telemetry models we use for GLP examinations of test articles and transformed the concept to create physiologically relevant screening models for lead compounds early in preclinical development.
GLP
Typical GLP dog or non-human primate telemetry studies average around six to eight subjects per interrogation and include a full protocol and report. Clients go back to their project teams with high fidelity assessments of effects on blood pressure, heart rate, ECG (including QT interval) and other parameters.
Lead Optimization
At the point of lead compound selection, however, project teams are trying to identify the most promising compound for advancement—thus we often compare one compound to another by rank order.
As a result, it’s often not necessary to invest in eight subjects on a screening study, nor have a full protocol or report. With lead optimization in mind, we design customized telemetry studies:
>> Generates data detecting subtle changes in CV parameters (such as QT interval) for screening purposes.
>> Leveraged in five species: dog, non-human primate, rabbit, rat and guinea pig telemetry.
>> Requires fewer animal subjects.
>> Efficient results with minimal paperwork.
The Bottomline
Telemetry screening allows clients to save money, use less test article and get results back to their colleagues in few days.
We’ve always known that time is money. But I believe our industry is also learning that good science decisions help us make better business decisions.
Regards,
Dr. Michael Gralinski, CorDynamics CEO
